Dra. Alicia van der Laat Muñoz

2017: Master in Molecular Oncology, Centro Nacional de Investigaciones Oncológicas, Spain.

2018: Diploma in Molecular Oncology, University of Liége, Belgium.

2016: Specialist in Medical Oncology, University of Costa Rica.

2014: Specialist in Internal Medicine, University of Costa Rica.

Professional Experiencel

• February 2018 to date:
  • Lecturer in Medical Oncology. University of Costa Rica.
• February 2016 to date:
  • Specialist in Medical Oncology. Hospital México.
  • Medical Oncology Specialist Centre for Research and Management of Cancer.
  • Undergraduate Professor of Internal Medicine University of Costa Rica.
  • Lecturer and consultant in specific areas of interest (skin, lung and breast cancers).

Application of chemotherapies and oncology therapies.

• Member of the European Society for Medical Oncology
• Member of the American Society of Clinical Oncology
• Member of the Costa Rican Association of Medical Oncologists
• Member of The International Association for the Study of Lung Cancer

• 2024:
  • Multidisciplinary Context in neoadjuvant treatment of Lung Cancer Centre for Treatment and Research on Cancer, Luis Carlos Sarmiento Angulo, Bogotá.
  • European Lung Cancer Congress, Prague.
  • Best of San Antonio in Breast Cancer, Costa Rica.
• 2023:
  • ESMO Congress 2023, Madrid, Spain.
  • Melanoma Bridge, Naples, Italy.
  • Immunotherapy Bridge, Naples, Italy.
• 2022:
  • ESMO Congress 2022, Paris, France.
• 2020:
  • Master in Thoracic Oncology. CEU Cardenal Herrera University.

Neoadjuvant metformin added to Systemic Therapy increases Pathological Complete Response in Breast cancer: A cross-sectional study, Hospital Mexico, Costa Rica. A Van Der Laat, D Landaverde; A. Ramos. Archives of Breast Cancer 2018; Vol 5, No1:32-37.

Allan Ramos-Esquivel, Alicia van der Laat, Raquel Rojas-Vigott, Melissa Juárez, Luis Corrales-Rodríguez. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open 2017;2: e000236. doi:10.1136/esmoopen-2017-000236.

Abstracts:

Neoadjuvant metformin along with systemic therapy increase pathological complete responses in breast cancer: Results of a cross-sectional study, Hospital Mexico, Costa Rica. A Van Der Laat, D Landaverde; J Clin Oncol 34, 2016 (suppl; abstr e12519).
First line treatment with Erlotinib in advanced non squamous NSCLC: our experience. CCSS, San José, Costa Rica. R Rojas, A van der Laat, A Ramos, 7th Latin American Conference on lung Cancer, IASLC, Panamá, 2016.

• Not available